Generic Name and Formulations:
Lorazepam 0.5mg, 1mg+, 2mg+; tabs; +scored.
Valeant Pharmaceuticals, Inc
Indications for ATIVAN:
Give in 2 or 3 divided doses, with largest dose taken at bedtime. Individualize. Initially 2–3mg daily; range: 1–10mg daily. Elderly or debilitated: initially 1–2mg daily; adjust gradually if needed.
Acute narrow-angle glaucoma.
Risks from concomitant use with opioids; see Interactions. Therapy for >4 months. Discontinue if paradoxical reactions occur. Primary depressive disorder or psychosis: not recommended. Suicidal tendencies (monitor). Renal or hepatic impairment. Compromised respiratory function. Seizure disorder. Reevaluate periodically. Monitor blood counts, liver function with long-term use. Abuse potential (monitor). Drug or alcohol abuse. Avoid abrupt cessation. Change dose gradually. Elderly. Debilitated. Pregnancy (during the 1st trimester), nursing mothers: not recommended.
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiation of CNS depression with alcohol, other CNS depressants (eg, barbiturates, antipsychotics, sedatives/hypnotics, anxiolytics, others). Caution with clozapine. May be potentiated by probenecid or valproate (reduce lorazepam dose by 50%). May be antagonized by theophylline, aminophylline.
CNS depression (esp. sedation), dizziness, weakness, unsteadiness, transient memory impairment, confusion, disorientation, nausea, change in appetite, headache, sleep apnea.
Tabs—100, 500, 1000
Clinical Pain Advisor Articles
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Pain Interference Associated With Depression, Pain Self-Efficacy in Chronic Musculoskeletal Pain
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Remission Rates and Predictors of Chronic Headache
- Overuse and Underuse of Imaging Common in Low Back Pain Management
- Unit-Dose Packaging of Buprenorphine-Naloxone Effective on Unintentional Pediatric Exposure
- Language Used in Medical Record Can Affect Patient Care
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes